Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study)

BACKGROUND: Tofacitinib is a Janus Kinase (JAK) inhibitor used for the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA), dosed as 5 mg twice daily (BID). It is primarily metabolized by the cytochrome P-3A (CYP3A) enzyme, and therefore, the manufacturer recommends to halve the dos...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Togt, Céleste J.T., Verhoef, Lise M., van den Bemt, Bart J.F., den Broeder, Nathan, ter Heine, Rob, den Broeder, Alfons A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749037/
https://www.ncbi.nlm.nih.gov/pubmed/36533097
http://dx.doi.org/10.1177/1759720X221142277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749037/
https://www.ncbi.nlm.nih.gov/pubmed/36533097
http://dx.doi.org/10.1177/1759720X221142277

Ejemplares similares